Assessing differential attrition in clinical trials: Self-monitoring of oral anticoagulation and type II diabetes

Carl Heneghan, Rafael Perera, Alison Ward A, David Fitzmaurice, Emma Meats, Paul Glasziou

Research output: Contribution to journalArticleResearchpeer-review

21 Citations (Scopus)
1 Downloads (Pure)

Abstract

Background: Analyzing drop out rates and when they occur may give important information about the patient characteristics and trial characteristics that affect the overall uptake of an intervention.

Methods: We searched Medline and the Cochrane library from the beginning of the databases to May 2006 for published systematic reviews that compared the effects of self-monitoring (self-testing) or self-management (self-testing and self-dosage) of oral anticoagulation or self-monitored blood glucose in type 2 diabetics who were not using insulin. We assessed all study withdrawals pre-randomization and post randomization and sought information on the reasons for discontinuation of all participants.

To measure the differential between groups in attrition we used the relative attrition ( RA), which is equivalent to relative risk but uses attrition as the outcome (i.e. attrition in intervention group/ attrition in control group). We determined the percentage drop outs for control and intervention groups and used DerSimonian and Laird random effects models to estimate a pooled relative attrition. L'abbe type plots created in R ( version 2.0.2) were used to represent the difference in the relative attrition among the trials with 95% confidence areas and weights derived from the random effects model.

Results: With self-monitoring of blood glucose in type 2 diabetes, attrition ranged from 2.3% to 50.0% in the intervention groups and 0% to 40.4% in the control groups. There was no significant difference between the intervention and control, with an overall RA of 1.18 [ 95% CI, 0.70 - 2.01]. With self-monitoring of oral anticoagulation attrition ranged from 0% to 43.2% in the intervention groups and 0% to 21.4% in the control group. The RA was significantly greater in the intervention group, combined RA, 6.05 [ 95% CI, 2.53 - 14.49].

Conclusion: This paper demonstrates the use of relative attrition as a new tool in systematic review methodology which has the potential to identify patient, intervention and trial characteristics which influences attrition in trials.

Original languageEnglish
Article number18
Number of pages12
JournalBMC Medical Research Methodology
Volume7
DOIs
Publication statusPublished - 2 May 2007
Externally publishedYes

Cite this

Heneghan, Carl ; Perera, Rafael ; A, Alison Ward ; Fitzmaurice, David ; Meats, Emma ; Glasziou, Paul. / Assessing differential attrition in clinical trials : Self-monitoring of oral anticoagulation and type II diabetes. In: BMC Medical Research Methodology. 2007 ; Vol. 7.
@article{e73a1cea611b48c797d4392f49292794,
title = "Assessing differential attrition in clinical trials: Self-monitoring of oral anticoagulation and type II diabetes",
abstract = "Background: Analyzing drop out rates and when they occur may give important information about the patient characteristics and trial characteristics that affect the overall uptake of an intervention.Methods: We searched Medline and the Cochrane library from the beginning of the databases to May 2006 for published systematic reviews that compared the effects of self-monitoring (self-testing) or self-management (self-testing and self-dosage) of oral anticoagulation or self-monitored blood glucose in type 2 diabetics who were not using insulin. We assessed all study withdrawals pre-randomization and post randomization and sought information on the reasons for discontinuation of all participants.To measure the differential between groups in attrition we used the relative attrition ( RA), which is equivalent to relative risk but uses attrition as the outcome (i.e. attrition in intervention group/ attrition in control group). We determined the percentage drop outs for control and intervention groups and used DerSimonian and Laird random effects models to estimate a pooled relative attrition. L'abbe type plots created in R ( version 2.0.2) were used to represent the difference in the relative attrition among the trials with 95{\%} confidence areas and weights derived from the random effects model.Results: With self-monitoring of blood glucose in type 2 diabetes, attrition ranged from 2.3{\%} to 50.0{\%} in the intervention groups and 0{\%} to 40.4{\%} in the control groups. There was no significant difference between the intervention and control, with an overall RA of 1.18 [ 95{\%} CI, 0.70 - 2.01]. With self-monitoring of oral anticoagulation attrition ranged from 0{\%} to 43.2{\%} in the intervention groups and 0{\%} to 21.4{\%} in the control group. The RA was significantly greater in the intervention group, combined RA, 6.05 [ 95{\%} CI, 2.53 - 14.49].Conclusion: This paper demonstrates the use of relative attrition as a new tool in systematic review methodology which has the potential to identify patient, intervention and trial characteristics which influences attrition in trials.",
author = "Carl Heneghan and Rafael Perera and A, {Alison Ward} and David Fitzmaurice and Emma Meats and Paul Glasziou",
year = "2007",
month = "5",
day = "2",
doi = "10.1186/1471-2288-7-18",
language = "English",
volume = "7",
journal = "BMC Medical Research Methodology",
issn = "1471-2288",
publisher = "BioMed Central Ltd.",

}

Assessing differential attrition in clinical trials : Self-monitoring of oral anticoagulation and type II diabetes. / Heneghan, Carl; Perera, Rafael; A, Alison Ward; Fitzmaurice, David; Meats, Emma; Glasziou, Paul.

In: BMC Medical Research Methodology, Vol. 7, 18, 02.05.2007.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Assessing differential attrition in clinical trials

T2 - Self-monitoring of oral anticoagulation and type II diabetes

AU - Heneghan, Carl

AU - Perera, Rafael

AU - A, Alison Ward

AU - Fitzmaurice, David

AU - Meats, Emma

AU - Glasziou, Paul

PY - 2007/5/2

Y1 - 2007/5/2

N2 - Background: Analyzing drop out rates and when they occur may give important information about the patient characteristics and trial characteristics that affect the overall uptake of an intervention.Methods: We searched Medline and the Cochrane library from the beginning of the databases to May 2006 for published systematic reviews that compared the effects of self-monitoring (self-testing) or self-management (self-testing and self-dosage) of oral anticoagulation or self-monitored blood glucose in type 2 diabetics who were not using insulin. We assessed all study withdrawals pre-randomization and post randomization and sought information on the reasons for discontinuation of all participants.To measure the differential between groups in attrition we used the relative attrition ( RA), which is equivalent to relative risk but uses attrition as the outcome (i.e. attrition in intervention group/ attrition in control group). We determined the percentage drop outs for control and intervention groups and used DerSimonian and Laird random effects models to estimate a pooled relative attrition. L'abbe type plots created in R ( version 2.0.2) were used to represent the difference in the relative attrition among the trials with 95% confidence areas and weights derived from the random effects model.Results: With self-monitoring of blood glucose in type 2 diabetes, attrition ranged from 2.3% to 50.0% in the intervention groups and 0% to 40.4% in the control groups. There was no significant difference between the intervention and control, with an overall RA of 1.18 [ 95% CI, 0.70 - 2.01]. With self-monitoring of oral anticoagulation attrition ranged from 0% to 43.2% in the intervention groups and 0% to 21.4% in the control group. The RA was significantly greater in the intervention group, combined RA, 6.05 [ 95% CI, 2.53 - 14.49].Conclusion: This paper demonstrates the use of relative attrition as a new tool in systematic review methodology which has the potential to identify patient, intervention and trial characteristics which influences attrition in trials.

AB - Background: Analyzing drop out rates and when they occur may give important information about the patient characteristics and trial characteristics that affect the overall uptake of an intervention.Methods: We searched Medline and the Cochrane library from the beginning of the databases to May 2006 for published systematic reviews that compared the effects of self-monitoring (self-testing) or self-management (self-testing and self-dosage) of oral anticoagulation or self-monitored blood glucose in type 2 diabetics who were not using insulin. We assessed all study withdrawals pre-randomization and post randomization and sought information on the reasons for discontinuation of all participants.To measure the differential between groups in attrition we used the relative attrition ( RA), which is equivalent to relative risk but uses attrition as the outcome (i.e. attrition in intervention group/ attrition in control group). We determined the percentage drop outs for control and intervention groups and used DerSimonian and Laird random effects models to estimate a pooled relative attrition. L'abbe type plots created in R ( version 2.0.2) were used to represent the difference in the relative attrition among the trials with 95% confidence areas and weights derived from the random effects model.Results: With self-monitoring of blood glucose in type 2 diabetes, attrition ranged from 2.3% to 50.0% in the intervention groups and 0% to 40.4% in the control groups. There was no significant difference between the intervention and control, with an overall RA of 1.18 [ 95% CI, 0.70 - 2.01]. With self-monitoring of oral anticoagulation attrition ranged from 0% to 43.2% in the intervention groups and 0% to 21.4% in the control group. The RA was significantly greater in the intervention group, combined RA, 6.05 [ 95% CI, 2.53 - 14.49].Conclusion: This paper demonstrates the use of relative attrition as a new tool in systematic review methodology which has the potential to identify patient, intervention and trial characteristics which influences attrition in trials.

U2 - 10.1186/1471-2288-7-18

DO - 10.1186/1471-2288-7-18

M3 - Article

VL - 7

JO - BMC Medical Research Methodology

JF - BMC Medical Research Methodology

SN - 1471-2288

M1 - 18

ER -